...
首页> 外文期刊>Liver international >Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions
【24h】

Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions

机译:CT/MRI LI-RADS 在肝细胞癌中的预后意义:现状和未来方向

获取原文
获取原文并翻译 | 示例

摘要

Hepatocellular carcinoma (HCC) is the fourth most lethal malignancy with an increasing incidence worldwide. Management of HCC has followed several clinical staging systems that rely on tumour morphologic characteristics and clinical variables. However, these algorithms are unlikely to profile the full landscape of tumour aggressiveness and allow accurate prognosis stratification. Noninvasive imaging biomarkers on computed tomography (CT) or magnetic resonance imaging (MRI) exhibit a promising prospect to refine the prognostication of HCC. The Liver Imaging Reporting and Data System (LI-RADS) is a comprehensive system for standardizing the terminology, techniques, interpretation, reporting and data collection of liver imaging. At present, it has been widely accepted as an effective diagnostic system for HCC in at-risk patients. Emerging data have provided new insights into the potential of CT/MRI LI-RADS in HCC prognostication, which may help refine the prognostic paradigm of HCC that promises to direct individualized management and improve patient outcomes. Therefore, this review aims to summarize several prognostic imaging features at CT/MRI for patients with HCC; the available evidence regarding the use of LI-RDAS for evaluation of tumour biology and clinical outcomes, pitfalls of current literature, and future directions for LI-RADS in the management of HCC.
机译:肝细胞癌 (HCC) 是全球第四大致死性恶性肿瘤,发病率不断上升。HCC 的管理遵循了几种依赖于肿瘤形态学特征和临床变量的临床分期系统。然而,这些算法不太可能分析肿瘤侵袭性的全部情况,也无法进行准确的预后分层。计算机断层扫描 (CT) 或磁共振成像 (MRI) 上的无创成像生物标志物在改善 HCC 预后方面显示出广阔的前景。肝脏成像报告和数据系统(LI-RADS)是一个综合系统,用于标准化肝脏成像的术语、技术、解释、报告和数据收集。目前,它已被广泛接受为高危患者肝癌的有效诊断系统。新出现的数据为CT/MRI LI-RADS在HCC预后中的潜力提供了新的见解,这可能有助于完善HCC的预后范式,有望指导个体化管理并改善患者预后。因此,本综述旨在总结HCC患者CT/MRI的几种预后影像学特征;关于使用LI-RDAS评估肿瘤生物学和临床结果的现有证据,当前文献的缺陷,以及LI-RADS在HCC管理中的未来方向。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号